Skip to Content

Skye Bioscience, Inc.

Securities Class Action

  • Date:
  • 1/16/2026
  • Company Name:
  • Skye Bioscience, Inc.
  • Stock Symbol:
  • SKYE
  • Class Period:
  • FROM 11/4/2024 TO 10/3/2025
  • Status:
  • Filed
  • Filing Date:
  • 11/17/2025
  • Court:
  • U.S. District Court: District of Southern California

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (“[Skye” or the “Company”) (NASDAQ:SKYE) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Investors have until January 16, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
 

Throughout the Class Period, Defendants made materially false and misleading statements regarding Skye’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) nimacimab was less effective than Defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

On October 6, 2025, Skye issued a press release “announc[ing] the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab[.]” The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”

On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.


If you purchased or otherwise acquired Skye shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Skye Bioscience. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: